Hypertension as cardiovascular risk factor in chronic kidney disease
M Burnier, A Damianaki - Circulation research, 2023 - Am Heart Assoc
Hypertension is the leading modifiable cause of premature death and hence one of the
global targets of World Health Organization for prevention. Hypertension also affects the …
global targets of World Health Organization for prevention. Hypertension also affects the …
[HTML][HTML] Links between metabolic syndrome and hypertension: the relationship with the current antidiabetic drugs
S Stanciu, E Rusu, D Miricescu, AC Radu, B Axinia… - Metabolites, 2023 - mdpi.com
Hypertension poses a significant burden in the general population, being responsible for
increasing cardiovascular morbidity and mortality, leading to adverse outcomes. Moreover …
increasing cardiovascular morbidity and mortality, leading to adverse outcomes. Moreover …
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
[PDF][PDF] 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
M Brunström, M Burnier… - Journal of …, 2023 - docred-strapi-cms-prod.s3.sa-east-1 …
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
AK Pandey, DL Bhatt, A Pandey, N Marx… - European heart …, 2023 - academic.oup.com
For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity
to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to …
to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to …
[HTML][HTML] Novel mechanisms of salt-sensitive hypertension
A high dietary sodium-consumption level is considered the most important lifestyle factor that
can be modified to help prevent an increase in blood pressure and the development of …
can be modified to help prevent an increase in blood pressure and the development of …
[HTML][HTML] Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
Cancer and cardiovascular disorders are known as the two main leading causes of mortality
worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related …
worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related …
Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: results of a 12‐week, multicentre, randomized, double‐blind …
YS Yang, KW Min, SO Park, KS Kim… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aims The study aimed to evaluate and compare the efficacy and safety of enavogliflozin, a
newly developed sodium‐glucose cotransporter 2 inhibitor, with placebo in Korean patients …
newly developed sodium‐glucose cotransporter 2 inhibitor, with placebo in Korean patients …
Blood pressure effects of SGLT2 inhibitors: mechanisms and clinical evidence in different populations
B Beal, AE Schutte, BL Neuen - Current Hypertension Reports, 2023 - Springer
Abstract Purpose of Review Sodium glucose transporter 2 inhibitors (SGLT2 inhibitors) are
increasingly prescribed due to their considerable benefits on clinical outcomes in people …
increasingly prescribed due to their considerable benefits on clinical outcomes in people …
[HTML][HTML] Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: the GliRACo study
AM Berton, M Parasiliti-Caprino, N Prencipe… - Frontiers in …, 2023 - frontiersin.org
Introduction In type 2 diabetes mellitus (T2DM), the antidiuretic system participates in the
adaptation to osmotic diuresis further increasing urinary osmolality by reducing the …
adaptation to osmotic diuresis further increasing urinary osmolality by reducing the …